ENT DISORDER TREATMENT MARKET ANALYSIS

Factors such as sinusitis and aging, affects normal functioning of ear, nose and throat. ENT is one of the most important branches of medical science, also known as otolaryngology, which is focused on diagnosis and treatment of disorders associated with ear, nose, and throat. Dysfunction of these organs may affect the person’s quality of life. Disorders related to ENT are treated with the help of devices as well as various classes of drugs. The report mainly covers drug classes and medical devices used for the treatment of disease such as sinusitis, rhinitis, otitis media, tonsillitis, and others.

The global ENT disorder treatment market is estimated to be valued at US$ 11,219.19 million in 2022 and is expected to exhibit a CAGR of 3.3% during the forecast period (2022-2030).

Figure 1. Global ENT Disorder Treatment Market Share (%), by End User, 2022

To learn more about this report, request a free sample copy

Increasing air and noise pollution is expected to aid in growth of ENT disorder treatment market

One of major factors leading to rise in number of ENT diseases is increasing air and noise pollution as well as bacterial concentration in the environment leading to various infections. According to the World Health Organization, 2017, around 40% of the European population is exposed to road traffic noise levels exceeding 55 decibels, leading to chronic hearing diseases such as loss of hearing, and earache. Moreover, air pollution can lead to throat infections as well as nasal infections leading to sinusitis and other disorders. According to the Centers of Disease Control and Prevention (CDC) 2017, around 25% of all hearing loss cases in Europe are due to noise and sound caused due to environmental pollution termed as Noise Induced Hearing Loss (NIHL). Moreover, excessive smoking can also lead to throat diseases leading to cancer.

Figure 2.Global ENT Disorder Treatment Market Share (%), by Region, 2022

To learn more about this report, request a free sample copy

New development of antibiotics and increasing approvals of antibiotics would provide opportunities for the market growth over the forecast years

Increasing new development and approvals of antibiotics is expected to drive the global ENT disorder treatment market over the forecast period. For instance, in August 2019,   The U.S. Food and Drug Administration approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. This new drug provided another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease. Lefamulin is a semisynthetic pleuromutilin antibiotic for community-acquired bacterial pneumonia.

Global ENT Disorder Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global ENT disorder treatment market, owing to the coronavirus mainly associated with the nose and throat infection. For instance, in June 2020, according to article published by National Center for Biotechnology Information, COVID-19 is presented mainly by lower respiratory tract related symptoms such as fever, cough, dyspnea and chest tightness that could progress rapidly to acute respiratory distress syndrome (ARDS). However, COVID-19 causes also different upper respiratory tract related symptoms including nasal congestion, sore throat and smell dysfunction. Among large number of research papers on COVID-19, eleven reviewed and published studies met the inclusion and exclusion criteria of the current review and reported ENT manifestation in COVID-19 positive patients. The nasal, nasopharyngeal and/or the orpharyngeal tissue is one of the main harbor sites of the infection, main site of taking the sample for testing and a main source of transmission of infection.

Global ENT Disorder Treatment Market: Key Developments

In October 2021, Acclarent, Inc., part of the Johnson & Johnson Medical Devices Companies, and a developer of minimally-invasive Ear, Nose, & Throat (ENT) technologies, announced the U.S. launched of its first-ever AI-powered ENT technology, designed to simplify surgical planning and provide real-time feedback during ENT navigation procedures. The new software package contains TruSeg and TruPath for use with the TruDi Navigation System and leverages a machine learning algorithm to provide reliable and efficient image guided preoperative planning and navigation for ENT procedures, like endoscopic sinus surgery.

Global ENT Disorder Treatment Market: Restraint

The major factors that hinder growth of the global ENT disorder treatment market include low awareness about treatment for ENT disorder in some emerging economies such as several African countries as well as threat of developing antibiotic resistance. For instance, in November 2017, according to Centers for Disease Control and Prevention, the threat of antibiotic resistance undermines progress in health care, food production, and life expectancy. The antibiotic resistance threats report also includes an estimate of the burden of Clostridioides difficile (C.difficile) infections, because C. difficile is caused by the same factors that drive antibiotic resistance—antibiotic use and the spread of germs. In 2017, nearly 223,900 people in the U.S. required hospital care for C. difficile and at least 12,800 people died.

Key Players

Major players operating in the global ENT disorder treatment market include Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddy’s Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc. and Zounds,Inc.